Clinical Trial Update: Does Omega-3 Polyunsaturated Fatty Acids (PUFAs) Pretreatment Improve Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI)? [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating whether pretreatment with omega-3 polyunsaturated fatty acids improves outcomes in patients undergoing percutaneous coron…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Arteriosclerosis

Drugs mentioned

• Omega-3 polyunsaturated fatty acids (omega-3 polyunsaturated fatty acids)

Snippet

Sponsor: Shiraz University of Medical Sciences | Conditions: Coronary Arteriosclerosis | Phase 3 | Status: UNKNOWN